ABCG2 regulates the pattern of self-renewing divisions in cisplatin-resistant non-small cell lung cancer cell lines

被引:33
作者
Tang, Ying [1 ]
Hou, Jingming [2 ]
Li, Guanghui [1 ]
Song, Zongchang [1 ]
Li, Xiaojing [1 ]
Yang, Cui [1 ]
Liu, Wenying [1 ]
Hu, Yide [1 ]
Xu, Yu [3 ]
机构
[1] Third Mil Med Univ, Xinqiao Hosp, Dept Oncol, Chongqing 400038, Peoples R China
[2] Chinese PLA Beijing Army Gen Hosp, Dept Orthoped, Beijing 100700, Peoples R China
[3] Third Mil Med Univ, Inst Resp Dis, Xinqiao Hosp, Chongqing 400038, Peoples R China
基金
中国国家自然科学基金;
关键词
ABCG2; drug resistance; NSCLC; symmetric division; asymmetric division; MULTIDRUG-RESISTANCE; STEM-CELLS; ASYMMETRIC DIVISION; DRUG-RESISTANCE; IN-VIVO; EXPRESSION; CHEMOTHERAPY; TRANSPORTER; SUPPRESSION; PHENOTYPE;
D O I
10.3892/or.2014.3470
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Overexpression of ABCG2 is considered a major mechanism of cancer drug resistance. Recent studies have shown that ABCG2 can regulate the switch between symmetric and asymmetric cell division in adult stem cells; however, the relationship between ABCG2 and cell division in drug-resistant cancer cells remains to be determined. In the present study, we demonstrated that ABCG2 is involved in the cell division of drug-resistant cancer cells. We first established drug-resistant H460 and A549 cell lines by repeated exposure to cisplatin and found that the expression of ABCG2 in these cell lines was significantly increased. As evidenced by PKH-26 staining, these drug-resistant cell lines favored symmetric division, which differed from the asymmetric division of the parental cells. Furthermore, we established stable ABCG2-overexpressing and stable shRNA-ABCG2-knock-down cell lines to evaluate the potential role of ABCG2 in cancer cell division. The results showed that overexpression of ABCG2 in A549 parental cells significantly increased the proportion of symmetric division, whereas knockdown of ABCG2 in drug-resistant A549 cells significantly increased the proportion of asymmetric division. Taken together, our findings suggest that ABCG2 is involved in the modulation of cancer drug resistance by regulating the pattern of cell division. The present study provides novel insight into the role of ABCG2 in cancer treatment resistance.
引用
收藏
页码:2168 / 2174
页数:7
相关论文
共 50 条
[21]   Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients [J].
Lemos, Clara ;
Giovannetti, Elisa ;
Zucali, Paolo A. ;
Assaraf, Yehuda G. ;
Scheffer, George L. ;
van der Straaten, Tahar ;
D'Incecco, Armida ;
Falcone, Alfredo ;
Guchelaar, Henk-Jan ;
Danesi, Romano ;
Santoro, Armando ;
Giaccone, Giuseppe ;
Tibaldi, Carmelo ;
Peters, Godefridus J. .
PHARMACOGENOMICS, 2011, 12 (02) :159-170
[22]   SKA1 regulates the metastasis and cisplatin resistance of non-small cell lung cancer [J].
Shen, Lihua ;
Yang, Min ;
Lin, Qionghua ;
Zhang, Zhongwei ;
Miao, Changhong ;
Zhu, Biao .
ONCOLOGY REPORTS, 2016, 35 (05) :2561-2568
[23]   Skp2-mediated MLKL degradation confers cisplatin-resistant in non-small cell lung cancer cells [J].
Zhou, Huiling ;
Zhou, Li ;
Guan, Qing ;
Hou, Xuyang ;
Wang, Cong ;
Liu, Lijun ;
Wang, Jian ;
Yu, Xinfang ;
Li, Wei ;
Liu, Haidan .
COMMUNICATIONS BIOLOGY, 2023, 6 (01)
[24]   miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2 [J].
Qiu, Tianzhu ;
Zhou, Li ;
Wang, Tongshan ;
Xu, Jing ;
Wang, Jian ;
Chen, Wenjiao ;
Zhou, Xin ;
Huang, Zebo ;
Zhu, Wei ;
Shu, Yongqian ;
Liu, Ping .
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2013, 32 (03) :593-598
[25]   Clinical Significance of ABCG2 Haplotype-tagging Single Nucleotide Polymorphisms in Patients With Unresectable Non-Small Cell Lung Cancer Treated With First-line Platinum-based Chemotherapy [J].
Kim, Seok-Hyun ;
Kim, Moon Jin ;
Cho, Yu Ji ;
Jeong, Yi Yeong ;
Kim, Ho-Cheol ;
Lee, Jong Duk ;
Hwang, Young Sil ;
Kim, In-Suk ;
Lee, Suee ;
Oh, Sung Yong ;
Ling, Hui ;
Lee, Gyeong-Won .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2015, 38 (03) :294-299
[26]   Alterations of microRNAs in Cisplatin-resistant Human Non-small Cell Lung Cancer Cells (A549/DDP) [J].
Wang, Qi ;
Zhong, Meizuo ;
Liu, Wei ;
Li, Jianhuang ;
Huang, Jin ;
Zheng, Le .
EXPERIMENTAL LUNG RESEARCH, 2011, 37 (07) :427-434
[27]   KRAS and EGFR Mutations Differentially Alter ABC Drug Transporter Expression in Cisplatin-Resistant Non-Small Cell Lung Cancer [J].
Jaromi, Luca ;
Csongei, Veronika ;
Vesel, Monika ;
Abdelwahab, ElHusseiny Mohamed Mahmud ;
Soltani, Amina ;
Torok, Zsofia ;
Smuk, Gabor ;
Sarosi, Veronika ;
Pongracz, Judit Erzsebet .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (10)
[28]   MICA enhances sensitivity to cisplatin in patients with extensive small cell lung cancer via downregulation of ABCG2 [J].
Wu, Yufeng ;
Tang, Hong ;
Si, Ruirui ;
Xia, Suhua ;
Wang, Ruilin ;
Wang, Qiming .
ONCOLOGY LETTERS, 2020, 20 (02) :1143-1152
[29]   Celecoxib Up Regulates the Expression of Drug Efflux Transporter ABCG2 in Breast Cancer Cell Lines [J].
Kalalinia, Fatemeh ;
Elahian, Fatemeh ;
Mosaffa, Fatemeh ;
Behravan, Javad .
IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2014, 13 (04) :1393-1401
[30]   Interleukin-7 Resensitizes Non-Small-Cell Lung Cancer to Cisplatin via Inhibition of ABCG2 [J].
Ke, Bin ;
Wei, Ting ;
Huang, Yuanyuan ;
Gong, Yuxin ;
Wu, Gang ;
Liu, Junfang ;
Chen, Xiaoting ;
Shi, Lin .
MEDIATORS OF INFLAMMATION, 2019, 2019